4 Jul 2018 14:15
Â
Â
Â
Â
4 July 2018 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Â
Notification of Preliminary Results
Â
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2018 on Thursday 12 July 2018.
Â
A meeting for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
Â
To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results:
Â
http://webcasting.buchanan.uk.com/broadcast/5afc4a0b1fcda841bf20f48dÂ
Â
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
Â
ENDS
Â
ENQUIRIES:
Â
Â
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Tilly Abraham | |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) | |
N+1 Singer Advisory LLP | +44 (0) 20 7496 3000 |
Mark Taylor (Joint Broker) |
Â
About ReNeuron
Â
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
Â
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
Â
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Â
Â